Kolexia
Vicier Cecile
Oncologie médicale
Centre Paoli-Calmettes
Marseille, France
114 Activités
292 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Carcinomes Néphrocarcinome Tumeurs de la prostate Tumeurs du sein triple-négatives Tumeurs de la vessie urinaire Tumeurs du cerveau Tumeurs du rein

Industries

B3TSI
17 collaboration(s)
Dernière en 2023
Pfizer
9 collaboration(s)
Dernière en 2023
Ipsen
6 collaboration(s)
Dernière en 2023
Daiichi Sankyo
5 collaboration(s)
Dernière en 2023

Dernières activités

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors: A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Essai Clinique (BMS)   06 mars 2024
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors: A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Essai Clinique (BMS)   09 février 2024
Study of DF1001 in Patients With Advanced Solid Tumors: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Essai Clinique (Dragonfly Therapeutics)   25 janvier 2024
EDEN: Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm Seminomas
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
Dr Mathilde GUERIN & Dr Cécile VICIER - Le cancer du testicule
Youtube @ Institut Paoli-Calmettes   01 décembre 2023
GETUG-StORM-01: A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Essai Clinique (Centre François-Baclesse)   31 juillet 2023
A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors: Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Essai Clinique (Merus N.V.)   07 mai 2023
189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
Abstract Book of ESMO Breast Cancer 2023, Berlin, Germany, 11-13 May 2023   01 mai 2023
ESME-MBC: Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
Essai Clinique (Seagen)   16 mars 2023
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.
ESMO open   13 décembre 2022